Kura Oncology (KURA) Q2 2024 earnings summary

Executive summary

• Achieved FDA Breakthrough Therapy Designation for ziftomenib in relapsed/refractory NPM1-mutant AML, with pivotal KOMET-001 trial fully enrolled and topline data expected early 2025.

• Advanced ziftomenib in combination trials (KOMET-007, KOMET-008), with robust enrollment and encouraging safety/activity profiles; updated data expected Q4 2024.

• IND clearance for ziftomenib plus imatinib in GIST, with proof-of-concept study to begin in H1 2025; preclinical data support expansion into diabetes.

• KO-2806 and tipifarnib are in clinical development for solid tumors and head and neck cancers, with first patient dosed in KO-2806/adagrasib NSCLC study.

• Strong financial position with $491.5M in cash, cash equivalents, and short-term investments as of June 30, 2024, supporting operations into 2027.

Financial highlights

• Q2 2024 R&D expenses were $39.7M, up from $28.2M in Q2 2023, mainly due to increased clinical trial costs.

• General and administrative expenses rose to $16.7M from $11.8M year-over-year.

• Net loss for Q2 2024 was $50.8M, compared to $37.2M in Q2 2023; net loss per share was $(0.59) vs. $(0.53).

• Cash, cash equivalents, and short-term investments totaled $491.5M as of June 30, 2024.

• Other income, net, was $5.6M in Q2 2024, up from $2.8M in Q2 2023, mainly due to higher interest income.

Outlook and guidance

• Cash runway expected to fund operations into 2027.

• Updated KOMET-007 combination data to be presented in Q4 2024; KOMET-001 topline data in early 2025.

• Proof-of-concept study for ziftomenib plus imatinib in GIST to start in H1 2025; next-generation menin inhibitor candidate nomination planned for early 2025.

• KO-2806 monotherapy maximum tolerated dose to be identified in H2 2024; KURRENT-HN expansion cohort enrollment to complete by year-end.

• Anticipates increased expenses as clinical development progresses and as general and administrative activities expand.